The Centers for Medicare & Medicaid Services (CMS) finalized the 2027 Medicare Advantage payment rate at a +2.48% net average increase, well above the +0.09% proposed in January and above the roughly 1% street expectation.
The decision injects over $13 billion into private insurers serving 35 million Medicare Advantage beneficiaries, triggering a broad relief rally across managed care stocks punished all year on fears of a near-flat rate environment.
Medicare Advantage is the private-insurer alternative to traditional Medicare. Insurers bid to cover seniors, and CMS sets benchmark payment rates annually. When rates rise meaningfully, insurers collect more per member, improving margins and enabling benefit enhancements that attract enrollment. When rates disappoint, benefit ratios deteriorate and earnings guidance gets cut.
These five stocks are the primary vehicles through which Wall Street bets on the senior healthcare market.
1. Humana (HUM)
Humana (NYSE:HUM | HUM Price Prediction) is the most distressed name in managed care and therefore has the most to gain. The stock is down 26.09% year to date and traded as low as $162.29 at its 52-week low. But shares of HUM got a big boost on Tuesday on the news, gaining 6.99% in a.m. trading.
A severe Star Ratings decline created a significant quality bonus payment headwind, driving guided adjusted EPS down from $17.14 in FY25 to at least $9.00 in 2026. With an Insurance segment benefit ratio of 93.1% in Q4 2025, Humana has operated with razor-thin margin. A higher rate environment directly lifts per-member revenue against that cost base. The company guided for roughly 25% individual MA membership growth in 2026, meaning a larger book of business benefits from each incremental basis point of rate improvement.
Analysts’ consensus target sits at $212.17. Humana reports Q1 2026 results on April 29, the first opportunity to quantify the rate tailwind in guidance language.
2. Alignment Healthcare (ALHC)
Alignment Healthcare (NASDAQ:ALHC) is the pure-play name in this group, with 100% of revenue tied to Medicare Advantage. That concentration means no rate improvement matters more here. The stock surged 17.57% on Tuesday in a.m. trading alone.
Alignment holds 100% of members are in 4-star or higher plans for the second consecutive year, including two 5-star contracts in Nevada and North Carolina. Its FY25 medical benefits ratio of 87.5% is best-in-class among these five peers, converting rate increases into margin more efficiently than competitors. Alignment guided for revenue of $5.135B to $5.190B in 2026 and membership of 292,000 to 298,000. The consensus analyst target is $25.50. Q1 results are expected around May 7.
3. UnitedHealth Group (UNH)
UnitedHealth Group (NYSE:UNH) carries the largest absolute Medicare Advantage revenue exposure, with UHC Medicare and Retirement revenue of $43.60 billion in Q4 2025, up 23% year over year. The stock rallied 9.50% in a.m. trading on Tuesday but remains down 8.47% on the year.
Bank of America raised its price target to $337. UnitedHealth’s situation is complicated by ongoing DOJ legal actions concerning Medicare program participation, a $2.88 billion pre-tax cyberattack charge, and a guided 2.3 to 2.8 million member reduction as the company exits unprofitable contracts. Still, the scale of its MA book means even modest per-member rate improvement translates to significant dollar impact. Q1 earnings are scheduled for April 21.
4. CVS Health (CVS)
CVS Health (NYSE:CVS) benefits through its Aetna unit, which generated Health Care Benefits revenue of $36.29 billion in Q4 2025, with government premiums growing 19.8% year over year to $26.56 billion. Aetna holds a strong Star Ratings position: More than 81% of members are in 4-star or higher plans for 2026, with over 63% in a 4.5-star plan. That quality positioning means Aetna captures quality bonus payments on top of the base rate increase, amplifying the benefit relative to lower-rated peers.
CVS rallied 6.67% in a.m. trading on Tuesday. The company’s 2026 adjusted EPS guidance of $7.00 to $7.20 was set before this rate finalization and may prove conservative. The analyst consensus target stands at $96.42. CVS reports Q1 results on May 6.
5. Elevance Health (ELV)
Elevance Health (NYSE:ELV) has the most diversified revenue base, with its Carelon Services segment generating Q4 revenue of $18.70 billion, up 27% year over year. That diversification cushions Medicare Advantage rate volatility but also means the rate decision is a partial rather than dominant driver. Medicare segment revenue was $10.76 billion in Q4 2025, up 18.9% year over year.
Elevance guided 2026 adjusted EPS at at least $25.50, down from $30.29 in FY25, and expressed confidence in returning to at least 12% adjusted EPS growth in 2027. The stock is down 12.01% year to date and trades at a forward P/E of 12x against an analyst target of $380.95. Q1 results are due April 22.
Conclusion
The 2027 MA rate finalization resolves the single largest policy uncertainty weighing on managed care valuations since January. The +2.48% final rate versus the feared +0.09% proposal improves per-member economics across the sector. Three themes dominate the forward outlook: Star Ratings divergence (Alignment Healthcare and Aetna are positioned to capture outsized quality bonuses while Humana faces continued headwinds); benefit ratio discipline (companies closest to breakeven on cost ratios gain the most leverage from incremental revenue); and Q1 earnings season, beginning with UnitedHealth on April 21, when management teams will formally update guidance incorporating the rate decision. The key remaining uncertainty is medical cost trend, which has run above expectations sector-wide and could absorb a meaningful portion of the rate increase before it reaches earnings.
Top Gaining Stocks
Top Losing Stocks